[Asia Economy Reporter Hyunseok Yoo] VIDI announced on the 26th that its U.S. subsidiary, Ellison Pharmaceuticals (Ellison), is seeking global partners for the pancreatic cancer second-line treatment drug "Glufosfamide," which is currently undergoing Phase 3 clinical trials.
Glufosfamide is currently progressing smoothly in Phase 3 clinical trials in the United States, involving 480 patients to date. Ellison is exploring partnerships for Glufosfamide in almost all regions, including the U.S., Europe, and Japan (excluding Korea, China, and Israel).
Ellison plans to participate in the "J.P. Morgan Healthcare Conference" held in San Francisco, USA, in January next year and is organizing a separate side event for partnership opportunities. Through this, they aim to strengthen networks with global pharmaceutical and biotech companies and actively seek partners with expertise and competitiveness.
Ellison signed a licensing agreement at the end of 2011 with Daewoong Pharmaceutical, one of Korea's top pharmaceutical companies. In China, in 2017, they signed licensing and development agreements with Lee’s Pharma, a large Chinese pharmaceutical company listed on the Hong Kong Stock Exchange. Additionally, in 2018, they signed a licensing agreement with Israel's Rafa Laboratories.
Edwin Thomas, CEO of Ellison, stated, "Ellison is considering a strategy to commercialize the new drugs currently under development in the U.S. and then distribute and sell them globally through partners. By leveraging partners' regulatory expertise, sales personnel, and marketing capabilities, we can maximize profits, and through strategic alliances with partners, we may also receive support for future clinical research and development funding, which is a significant advantage."
He added, "Through participation in the 'J.P. Morgan Healthcare Conference 2022,' we plan to showcase the excellence of Ellison's pipeline," and said, "We will do our best to gain recognition for growth potential from the American Medical Association and various investors, while also securing licensing agreements for commercial rights from potential global partners."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
